Compounds > nitroacridine 3582
Page last updated: 2024-11-07

nitroacridine 3582

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitroacridine 3582: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115023
CHEMBL ID529691
SCHEMBL ID2544885
MeSH IDM0119350

Synonyms (26)

Synonym
nitroacridine 3582
nitroakridin 3582
brn 0370438
netoxon
9-((3-diethylamino-2-hydroxypropyl)amino)-2,3-dimethoxy-6-nitroacridin
1-(diethylamino)-3-((2,3-dimethoxy-6-nitro-9-acridinyl)amino)-2-propanol
2-propanol, 1-(diethylamino)-3-((2,3-dimethoxy-6-nitro-9-acridinyl)amino)-
nsc13003
1-(diethylamino)-3-[(2,3-dimethoxy-6-nitro-acridin-9-yl)amino]propan-2-ol
2-propanol, 1-(diethylamino)-3-[(2,3-dimethoxy-6-nitro-9-acridinyl)amino]-
1-(diethylamino)-3-[(2,3-dimethoxy-6-nitroacridin-9-yl)amino]propan-2-ol
CHEMBL529691
4-21-00-06563 (beilstein handbook reference)
unii-75t5asd975
75t5asd975 ,
6035-39-8
nitroacridine-3582
nitroakridin 3582 [mi]
(+/-)-nitroacridine 3582
l-280401
nitroakridin
nitroakridin-3582
SCHEMBL2544885
DTXSID20975761
1-(diethylamino)-3-[(2,3-dimethoxy-6-nitroacridin-9(10h)-ylidene)amino]propan-2-ol
Q27266406

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Although the intercalating ability of these ring systems lead to high sensitivity for detection of reduced metabolites in vitro by flow cytometry, poor bioavailability is an unwanted consequence of intercalation."( Nitroaryl compounds as potential fluorescent probes for hypoxia. I. Chemical criteria and constraints.
Clarke, ED; Hodgkiss, RJ; Middleton, RW; Parrick, J; Stratford, MR; Wardman, P, 1984)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		3.2160aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
ConditionIndicatedRelationship StrengthStudiesTrials
Ornithosis
[description not available]		01.9210
Lymphogranuloma Inguinale
[description not available]		01.9210
Psittacosis
Infection with CHLAMYDOPHILA PSITTACI (formerly Chlamydia psittaci), transmitted to humans by inhalation of dust-borne contaminated nasal secretions or excreta of infected BIRDS. This infection results in a febrile illness characterized by PNEUMONITIS and systemic manifestations.		01.9210
Benign Neoplasms
[description not available]		01.9610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9610
Experimental Neoplasms
[description not available]		02.3720